CAS |
No.1223403-58-4 |
中文名称 |
拉罗替尼 |
英文名称 |
LOXO-101 |
分子式 |
C21H22F2N6O2 |
分子量 |
428.44 |
溶解性 |
Soluble in DMSO |
纯度 |
≥98% |
外观(性状) |
Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
MDL |
MFCD28902192 |
SMILES |
C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C= CC(=C5)F)F |
InChIKey |
C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C= CC(=C5)F)F |
InChI |
InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26- 19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2, 5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1 |
PubChem CID |
46188928 |
靶点 |
Trk Receptor |
通路 |
Protein Tyrosine Kinase/RTK;Neuronal Signaling |
背景说明 |
LOXO-101是一种 ATP 竞争性的、选择性TRK抑制剂。 |
生物活性 |
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).[1-4] |
In Vitro |
Larotrectinib (LOXO-101) 是原肌球蛋白相关激酶 (TRK) 受体激酶家族 (TRKA、B 和 C) 的 ATP 竞争性口服抑制剂,对所有三种亚型具有低纳摩尔半抑制浓度,以及相对于其他激酶的选择性大于 1,000 倍[1][2]。用 Larotrectinib (LOXO-101) 处理后的增殖测量表明,所有三种细胞系的细胞增殖都受到剂量依赖性抑制。对 CUTO-3.29 的 IC50 小于 100 nM,KM12 和 MO-91 的 IC50 小于 10 nM,这与该药物对 TRK 激酶家族的已知效力一致[3]。 |
In Vivo |
在大鼠和猴子研究中,Larotrectinib (LOXO-101) 表现出 33-100% 的口服生物利用度和 60-65% 的血浆蛋白结合率。它具有低脑渗透性,并且在 28 天 (d) GLP 毒理学研究中具有良好的耐受性。单剂量 (30 mg/kg) Larotrectinib (LOXO-101) 可降低肿瘤中 TRKA 的酪氨酸磷酸化和下游信号转导 (pERK) >80%[1]。注射 KM12 细胞的无胸腺裸鼠每天口服 Larotrectinib (LOXO-101),持续 2 周。观察到剂量依赖性肿瘤抑制,证明了这种选择性化合物在体内抑制肿瘤生长的能力[4]。与媒介物处理的小鼠相比,Larotrectinib (LOXO-101) (200 mg/kg/天,口服给药,持续六周) 可将骨髓和脾脏中的白血病浸润减少到检测不到的水平。根据 Xenogen 成像的测定,接受 Larotrectinib (LOXO-101) 处理的小鼠在停止处理 4 周后仍然存活并且没有白血病[5]。 |
动物实验 |
Mice[4]Athymic nude mice are used throughout the study. 5×105 KM12 cells are injected subcutaneously into the dorsal flank area of the mice. Tumor volume is monitored by direct measurement with calipers and calculated by the formula: length × (width2)/2. Following the establishment of tumor and when the tumor size is between 150-200 mm2, mice are randomly selected to receive diluent, 60 mg/kg/dose or 200 mg/kg/dose of Larotrectinib (LOXO-101). Larotrectinib (LOXO-101) is administered by oral gavage once daily for 14 days. After the last dose, tissue and blood are collected at 3, 6 and 24 hours post-treatment[4]. |
数据来源文献 |
[1]. Karyn Bouhana, et al. LOXO-101, a pan TRK inhibitor, For The Treatment Of TRK-driven Cancers. [2]. Nagasubramanian R, et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. [3]. Kathryn G, et al. Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood 2016 128:278. [4]. Doebele RC, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57. |
规格 |
1mg 5mg 10mg 50mg 100mg |
单位 |
瓶 |